Энап (Enalapril) is a prescription medication utilized to support the management of certain cardiovascular conditions.

Quick Facts: Therapeutic Areas

• High Blood Pressure (Hypertension): Used to achieve and maintain reduced blood pressure levels.
• Heart Failure: Employed in the care plan for individuals managing symptomatic heart failure, typically alongside other medical interventions.
• Asymptomatic Left Ventricular Dysfunction (LVD): Indicated to assist in the management of asymptomatic LVD, which may contribute to a reduction in the subsequent development of symptomatic heart failure.

This medication is part of a broader therapeutic approach and its effects are aimed at regulating blood pressure and supporting heart function.

Who can and cannot use Энап?

Eligibility to use Энап (Enalapril) is strictly defined by regulatory authorities based on patient history, age, concurrent medications, and specific health conditions. The medicine is primarily intended for adults but is also approved for children and adolescents (1 month to 16 years) specifically for hypertension.

---

Eligibility Status	Official Regulatory Rule
Absolute Contraindications	History of angioedema related to any ACE inhibitor; hereditary or idiopathic angioedema; known hypersensitivity to enalapril; and use during the second and third trimesters of pregnancy [1.2, 2.2].
Prohibited Combinations	Use with sacubitril/valsartan is prohibited (must allow a 36-hour washout period) [1.2, 2.3]. Use with aliskiren is contraindicated in patients with diabetes or moderate/severe renal impairment [1.2, 2.3].
Conditional/Restricted Use	Caution is required for use in older adults and patients with impaired renal function, liver disease, or heart valve obstruction (aortic/mitral stenosis) [1.1, 2.2]. Discontinuation is advised during breastfeeding [1.2].
Age-Related Restrictions	The medicine is not recommended for neonates (infants 1 month of age or less) or for any pediatric patient with severe renal impairment (GFR <30 mL/min/1.73 m^2) [1.2, 2.2].

---

Regulatory documents establish that use is only permitted under controlled conditions for specific populations and is prohibited for groups with severe angioedema risk or during the critical later stages of pregnancy.

Interactions with other medicines and products

This section summarizes officially documented drug interactions for Энап (Enalapril maleate), based strictly on government regulatory labeling. This information details which substances interact and the resulting regulatory restrictions.

Official Interaction Constraints

Classification	Interacting Agents / Products	Documented Regulatory Constraint
Contraindicated	Sacubitril/valsartan	Must not be administered within 36 hours of switching to or from this combination due to high angioedema risk.
Contraindicated	Aliskiren-containing products	Prohibited in patients with diabetes mellitus or established renal impairment (GFR <60 mL/min/1.73 m^2).
Contraindicated	High-flux membranes (e.g., AN 69®)	Restricted use during haemodialysis due to risk of anaphylactoid reactions.
Caution / Monitoring	Potassium-sparing diuretics (e.g., amiloride, spironolactone) & Potassium supplements/Salt substitutes	Increased risk of hyperkalemia (high serum potassium levels).
Caution / Monitoring	Lithium	Documented potential for increased serum lithium concentrations and toxicity.
Caution / Monitoring	NSAIDs (e.g., ibuprofen, selective COX-2 inhibitors)	May result in deterioration of renal function, particularly in the elderly or volume-depleted patients.
Timing-Separation	Diuretics	Discontinuation of diuretic therapy for 2–3 days prior to initiating Enap may be suggested to minimize the risk of symptomatic hypotension.

Interaction Profile Summary

Enalapril’s interaction profile is primarily defined by pharmacodynamic effects, creating risks of hyperkalemia with potassium-retaining agents and marked hypotension when combined with other blood pressure-lowering agents, including diuretics. The label explicitly forbids co-administration with Neprilysin inhibitors and specifies condition-dependent contraindications for dual blockade of the Renin-Angiotensin System. Food intake does not influence the absorption of Enalapril.

Энап, which contains the prodrug enalapril, is bioactivated primarily in the liver via hydrolysis to its active metabolite, enalaprilat. Enalaprilat functions as a competitive inhibitor of angiotensin-converting enzyme (ACE), a peptidyl dipeptidase expressed extensively in vascular tissue, the kidneys, and the heart.

ACE is the biological target responsible for catalyzing the conversion of the decapeptide angiotensin I to the potent octapeptide angiotensin II. By inhibiting ACE, enalaprilat reduces the systemic and local concentrations of angiotensin II. This decrease results in reduced signaling through angiotensin II type 1 ( AT1) receptors, leading to decreased vasoconstriction and lower secretion of aldosterone from the adrenal cortex. Additionally, ACE is identical to kinase II, which catalyzes the degradation of the potent vasodepressor peptide, bradykinin. Inhibition of ACE therefore also leads to increased systemic levels of bradykinin.

The collective downstream effects include a reduction in total peripheral arterial resistance and a decrease in sodium and water retention at the renal level. System-level physiological modulation involves a net vasodilation and a reduction in circulating volume.

How to Use Enalapril (Энап) — Administration Instructions

The following information describes the administration and dosing rules for enalapril, the active ingredient in products like Энап.

Administration and Dosage

Component	Instruction
Route of Administration	Oral (Tablet) or Intravenous (IV) Infusion (as enalaprilat)
Timing Relative to Meals	Oral tablets may be taken with or without food.
Frequency	Typically taken once daily (OD). In some cases, the total dose may be divided and taken twice daily (BID).

Dosing Rules

Treatment must begin with a low initial dose and be gradually adjusted. The specific starting dose is conditional on the patient's clinical status and kidney function.

• Typical Oral Initial Dose: Ranges from 2.5 mg to 5 mg once daily.
• Oral Maintenance Dose: Typically 10 mg to 20 mg once daily, with a usual maximum of 40 mg per day.
• IV Administration: Reserved for short-term use when oral intake is not feasible. The dose (usually 1.25 mg of enalaprilat) is administered via slow IV injection, typically every 6 hours as needed.

Special Procedural Requirements

1. Kidney Impairment: Patients with reduced kidney function require a lower starting dose (e.g., 2.5 mg oral), which is determined by objective measures of renal clearance.
2. Use of Diuretics: If the patient is concurrently taking water pills (diuretics), a lower initial dose of enalapril must be used, and the diuretic may need to be temporarily discontinued.
3. Consistency: Oral administration should occur at approximately the same time each day to maintain consistent medicine levels.
4. Missed Dose: If an oral dose is missed, it should be skipped, and the next dose should be taken at the regularly scheduled time. A double dose should not be taken to compensate.

Research evidence / Overview of Studies for Энап (Enalapril)

---

Evidence for Use in Arterial Hypertension (High Blood Pressure)

The research base for enalapril for the condition of high blood pressure was established through numerous Randomized Controlled Trials (RCTs). The main outcomes that studies explored were changes in blood pressure measurements, and the long-term observation of the incidence of major cardiovascular events like stroke or heart attack. The findings describe patterns observed in the studies related to changes in blood pressure measurements achieved over time. Comparative evidence is lacking from dedicated, large-scale RCTs when exploring enalapril against some of the newest medications used today.

---

Evidence for Use in Symptomatic Chronic Heart Failure

The research base for enalapril for symptomatic chronic heart failure is grounded in major, long-term, placebo-controlled RCTs. The primary endpoints that studies explored were all-cause mortality, death due to cardiovascular causes, and the rate of hospitalization due to heart failure. Additionally, research highlights changes measured during the study period related to the patients' daily functioning. Long-term trials documented the overall rates of death and hospitalization observed over follow-up periods that averaged several years, contributing to the evidence base for the condition.

What remains uncertain includes the utility of enalapril for Heart Failure with Preserved Ejection Fraction (HFpEF); the research exploring this scenario findings were mixed and evidence is limited compared to the robust data for reduced ejection fraction.

---

Long-Term Studies and Durability of Follow-up

For both symptomatic heart failure and the prevention of LVD progression, the evidence was studied for significant durations, with average observation periods extending from three to over four years. The evidence contributes to understanding symptom patterns and event rates observed over these long time intervals. However, evidence derived from settings beyond the initial duration of the main controlled trials may rely on less controlled, observational data extensions, where evidence quality varies across studies.

Key Studies & References

1. The SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. (SOLVD Prevention Trial)
2. Enalapril - StatPearls (for indications and summary of evidence)

Common questions about Энап (FAQ)

Q: How quickly does Энап usually start to lower blood pressure?

Official product information describes the onset of the blood pressure-lowering effect as typically occurring about one hour after administration. The medicine generally reaches its peak effect within 4 to 6 hours.

Q: How long does the effect of one dose of Энап last?

Studies indicate that the blood pressure-lowering effect has been shown to be maintained for at least 24 hours at recommended doses. The duration of the drug’s effect may vary based on factors such as the administered dose.

Q: Is Энап generally used for long-term treatment?

Yes, regulatory documents indicate that this medication is used for the long-term management of chronic conditions, including arterial hypertension (high blood pressure) and certain types of chronic heart failure.

Q: What is the process for monitoring a person while they are on Энап?

Regulatory guidelines specify that a person's health should be checked at regular visits. These check-ups are intended to help evaluate the medicine’s activity and look for any unwanted effects or changes in health.

Q: Does taking Энап require regular blood tests?

Official warnings indicate that blood and urine tests may be required periodically to monitor for potential changes, such as high potassium levels (hyperkalemia) or changes in kidney function.

Q: Are headaches a known side effect of Энап?

Yes, official product information lists headaches as a common side effect. This is one of the many reactions documented in regulatory safety materials.

Q: Can I crush or split Энап tablets?

According to regulatory administration guidance, Энап tablets can be crushed and suspended in water for consumption. If the tablets are crushed and suspended in water, the official guidance indicates the mixture should be consumed immediately after being prepared.

Q: Does Энап help protect the heart?

The medicine is indicated for the treatment of heart failure and for the prevention of symptomatic heart failure in some patients. This is related to the drug's role in clinical trials, which documented a tendency to retard progressive cardiac enlargement in certain populations.

Q: What happens if I forget to take a dose of Энап?

If a dose is missed, it can lead to a diminishment of the blood pressure-lowering effect toward the end of the dosing interval. Official instructions state that you should skip the missed dose and take the next dose at the regularly scheduled time.

Q: Are there any common side effects people report when starting Энап?

Some side effects, such as dizziness, are described in official documents as being most commonly observed when a person first starts taking the medicine or after a dose increase.

Q: Can Энап cause a persistent dry cough?

Yes, a dry, tickly cough is a common, documented side effect of this class of medicine. This cough may start at any time during treatment but typically resolves within 1 to 4 weeks after the medication is discontinued.

Q: Is it normal to feel dizzy when first taking Энап?

Yes, dizziness is listed as a very common reaction. This feeling is described in regulatory materials as more likely to occur when starting the medicine or following a dose increase.

Q: Is it common for blood pressure to rise again if Энап is stopped?

Regulatory guidance advises against abruptly stopping this medication due to the documented potential for rebound hypertension, which is a rapid increase in blood pressure. The hypotensive effect may also persist for some time after the medicine is stopped.

Q: Does Энап affect blood sugar levels?

Official product information indicates that the medicine has been observed to lower the blood sugar level in the blood. For this reason, diabetic patients are advised to monitor their glucose levels more frequently, especially when starting the treatment.

Q: Is fatigue a possible side effect of Энап?

Tiredness (often described as fatigue) is listed as a possible side effect in official documents. It is documented as a common adverse reaction in the safety profile.

Q: Does Энап interact with herbal supplements?

Official regulatory sources state that there is not enough official information to confirm the safety of mixing with herbal remedies or supplements. This is based on the regulatory statement that these products are typically not subject to the same controlled testing for interactions.

Q: Why do doctors check liver function before prescribing Энап?

The active form of the medicine is created primarily in the liver. This caution relates to the fact that the medicine is processed there, and rare but serious liver problems, such as acute liver injury, have been documented as possible adverse reactions.

Q: Are there reported cases of withdrawal effects when stopping Энап?

The official documentation does not use the specific term 'withdrawal effects.' However, guidance does note that abrupt cessation can lead to the risk of rebound hypertension and advises monitoring when stopping the medication.

Q: Are there specific patient groups where Энап is used with caution?

Yes, caution is required for people who have certain pre-existing conditions, such as collagen vascular disease. It is also used cautiously in people who are simultaneously taking medicines like allopurinol or immunosuppressant therapy, particularly if they have existing kidney issues.

Q: Does alcohol interact with Энап?

Official interaction guidance indicates that alcohol and the medicine may have additive effects in lowering blood pressure. This combined action can increase the risk of symptoms like dizziness and is most likely to occur at the start of treatment.

Q: Is Энап appropriate for children or adolescents?

The medicine is officially approved for treating high blood pressure in children and adolescents ranging from one month to 16 years of age. However, it is not recommended for infants younger than one month or any child with severe kidney impairment.

Enalapril maleate tablets, the active ingredient in Энап, must be stored and handled according to specific regulatory requirements to ensure stability and safety.

Storage Requirements

Requirement	Official Condition (Tablets)
Temperature	Controlled Room Temperature (20 C to 25 C)
Protection	Protected from moisture; container kept tightly closed
Handling	Do not freeze the tablets
Child Safety	Must be stored out of the sight and reach of children

️ Disposal Instructions

Official guidelines state that unused or expired tablets must not be disposed of in household trash or flushed down the toilet, to prevent environmental contamination. Patients should ask a pharmacist for guidance on proper disposal, which typically involves utilizing official drug take-back programs or designated collection points.